微生物“合成”大未来

Core Viewpoint - The article highlights the rapid growth and innovation in the synthetic biology industry in Wuqing, Tianjin, particularly through the success of Tianjin Xiaowei Biotechnology Co., Ltd., which focuses on the development and production of probiotics, showcasing a shift towards domestic production and technological advancement in the sector [2][3][5]. Company Summary - Tianjin Xiaowei Biotechnology Co., Ltd. has grown into a leading enterprise in the probiotic industry, with over 10,000 strains collected and preserved, and 52 mature production strains [3]. - The company has developed 21 invention patents and collaborates with multiple research institutions, contributing to the development and production transformation of over 20 strains [3]. - The expected annual output value for the company is projected to exceed 50 million yuan, with plans for further capacity expansion in Wuqing [3]. Industry Summary - Wuqing has established a synthetic biology industry ecosystem that includes gene sequencing, gene synthesis, strain screening, and industrial fermentation, supported by leading projects such as the Tianjin University Synthetic Biology Frontier Research Institute [5][6]. - The research institute has successfully created a synthetic pathway for rose alcohol in yeast, marking a significant advancement in green and sustainable biomanufacturing [5]. - The region is home to 300 biopharmaceutical companies, with 56 of them being above-scale enterprises, and has achieved an industrial output value of 4.336 billion yuan from January to October 2025 [8]. - The Wuqing district aims to develop a trillion-level biopharmaceutical industry cluster, integrating biopharmaceuticals, medical devices, precision medicine, and synthetic biology manufacturing [8].